BGI VISTA™ PGT-A Preimplantation Genetic Testing

BGI VISTA™ PGT-A (Preimplantation Genetic Testing for Aneuploidy) is a highly accurate genetic test performed on embryos as part of an assisted reproductive technology program prior to implantation. The purpose of the test is to identify euploid (chromosomally normal) embryos to increase the likelihood of a successful clinical pregnancy and the birth of a healthy child.

Technology

BGI uses whole-genome amplification from a single cell (single-cell WGA) in combination with low-coverage whole-genome sequencing (low-pass WGS), which allows for:

• Detect aneuploidies across all 46 chromosomes
• Identify deletions or duplications larger than 4 Mb

Indications for Testing

• Women aged 35 or older
• Patients with recurrent pregnancy loss
• Couples with two or more unsuccessful IVF cycles
• Male factor infertility (low sperm count or poor sperm quality)
• Presence of chromosomal abnormalities in the couple or in previous children

Benefits

• Reduced rate of pregnancy loss due to the selection of euploid embryos
• Increased implantation and clinical pregnancy rates
• Fewer IVF cycles—saving time and resources
• High accuracy (>99.9%) thanks to the use of next-generation sequencing technology

PGT-A from BGI is an effective solution for optimizing IVF programs, improving their success rates, and reducing genetic risks even before pregnancy occurs.